IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY (IGAN) explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY (IGAN) trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY (IGAN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults will receive either …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jul 02, 2026 07:00 UTC
-
New drug combo aims to tame rare kidney diseases
Disease control Recruiting nowThis Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug zigakibart aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY (IGAN)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC